Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alflutinib vs Alflutinib + Chemotherapy in EGFR T790M+ NSCLC
NCT05209256Phase 3Unknown
- Sponsor
- First Affiliated Hospital of Henan University of Science and Technology
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Henan University of Science and Technology. Status: unknown.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05209256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05209256.